干扰素在毛细胞白血病中的当前作用:临床与分子层面
该回顾性分析纳入74例毛细胞白血病患者,分三组:A组>65岁初治、B组有合并症初治、C组嘌呤类似物耐药。总缓解率94%,完全缓解率24%;中位随访60个月,55例(78%)仍持续缓解。A、B、C组5年无进展生存率分别为95%、68%、96%。部分患者监测BRAF-V600E状态,干扰素α仍是特定患者的可选方案。
要点
- 干扰素α在特定毛细胞白血病患者中仍为可选治疗。
- 总缓解率94%,完全缓解率24%。
- 中位随访60个月,78%患者持续缓解。
核心结论
- 干扰素α仍是特定毛细胞白血病患者的可能选择,可实现微小残留病阴性。
研究设计与样本
- 回顾性分析74例毛细胞白血病患者,分为三组:A组>65岁初治、B组有合并症初治、C组嘌呤类似物耐药。
主要发现
- 总缓解率94%,完全缓解率24%。
- 中位随访60(7-236)个月,55例(78%)仍持续缓解。
- 5年无进展生存率:A组95%、B组68%、C组96%。
- 部分患者监测BRAF-V600E状态。
临床怎么用
- 对特定毛细胞白血病患者(如>65岁、有合并症或嘌呤类似物耐药)可考虑干扰素α治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated the current role of interferon-alpha (IFNα) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first-line treatment; (B) patients with comorbidities with first-line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. After a median (range) follow-up of 60 (7-236) months, 55 patients (78%) are still responding. The 5-year progression-free survival was 95%, 68%, and 96% in groups A, B and C respectively. A proportion of patients were monitored through their B-Raf proto-oncogene, serine/threonine kinase (BRAF)-V600E status. IFNα remains a possible option in select patients with HCL, where minimal residual disease negativity is achievable.
引用
- Assanto GM, Riemma C, Malaspina F, et al. The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. Br J Haematol. 2021. PMID: 33932027. doi:10.1111/bjh.17440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。